Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeCLINICAL TRIALS, STUDIES, DATASurfacide Peer-Reviewed Study: Confirms UV-C Extremely Effective in Killing SARS-CoV-2 On Surfaces...

Surfacide Peer-Reviewed Study: Confirms UV-C Extremely Effective in Killing SARS-CoV-2 On Surfaces and Air in Environments

Surfacide notes A recent peer-reviewed studyin the Journal of Clinical Anesthesia* found the Surfacide Helios System UV-C technology is nearly 95% effective in preventing SARS CoV-2 in patient environments.

This is the first clinical study that evaluates the use of UV-C in operating rooms, compared to previous studies conducted in a controlled lab environment.

The study was led by Dr. Randy Loftus, MD, an Associate Professor of Anesthesiology and Critical Care Medicine at University of Iowa Hospital and Clinics, and Dr. Franklin Dexter, MD, PhD, University of Iowa Professor in the Department of Anesthesia. Dr. Loftus has received national and international recognition for his expertise regarding the epidemiology of intraoperative pathogen transmission. View the study here.

In the last 10 years he has made numerous contributions to science as is reflected in a solid body of published evidence, including a focus on infection prevention protocols in the perioperative space. Dr. Dexter and his colleagues have developed much of the science in anesthesia group and operating room management.

For this study, Surfacide’s Helios System was deployed—the world’s first and only patented trio of UV light-emitting ‘robots’ that simultaneously provide floor to ceiling UV-C energy. A total of 473 intraoperative reservoir samples were tested among 13 anesthesia work areas and 12 environmental locations. The following results were confirmed:

  • Environmental locations tested monitored proximal sites exposed to droplet spread and more distal sites potentially impacted by aerosolized particles.
  • Use of Surfacide UV-C disinfection showed nearly a 2-fold reduction in SARS-CoV-2 detection as compared to traditional surface disinfection cleaning procedures without UV-C.
  • Surface disinfection cleaning alone is associated with greater environmental detection of SARS-CoV-2.
  • The Surfacide technology was associated with decreased residual contamination of distal sites impacted by aerosolization.

“This study further validates Surfacide’s effectiveness as a critical infection control measure in combating deadly pathogens in real world environments,” said Surfacide Founder and CEO Gunner Lyslo. “Surfacide’s triple-emitter, floor to ceiling UV technology, along with its effectiveness in inactivating aerosolized pathogens AND pathogens colonizing surfaces, makes this study a game-changer in infection prevention and confirms that not all UV-C is created equal.”

The data presented in this paper emphasizes the importance of Surfacide UV-C as an infection control measure against pathogens found on surfaces and in the air, especially within the operating room space. Surfacide’s evidence-based approach is critical in providing a safer environment for healthcare staff and patients alike. It’s proven ability, as documented in this study, sets this technology apart from all other UV devices.

*R.W. Loftus, F. Dexter, L.C. Evans, et al., An assessment of the impact of recommended anesthesia work area cleaning procedures on intraoperative SARS-CoV-2 contamination, a case-series analysis, Journal of Clinical Anesthesia (2021)


Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy